Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Fujisawa Healthcare and Roche Pharmaceuticals have formed a partnership for the US co-promotion of Mycamine injection, Fujisawa's newly approved product for esophageal candidiasis and Candida infections.
Subscribe to our email newsletter
Mycamine (micafungin sodium), an antifungal in the echinocandin class, was approved by the FDA on March 16, 2005 for the treatment of patients with esophageal candidiasis and for the propylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. It is the first echinocandin approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Under the announced agreement, Roche will utilize its hospital sales force to augment Fujisawa’s promotion of Mycamine throughout the US. Fujisawa will book sales and compensation to Roche will be based on product sales.
“Fujisawa is proud to welcome Roche among our impressive list of business partners,” stated Dr William Fitzsimmons, senior vice president of business development at Fujisawa. “Our collaboration with Roche for the co-promotion of Mycamine will allow us to reach further into the competitive hospital setting to bring this new therapeutic option to a greater number of physicians and the patients they treat.”